Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Stroke

Free Subscription Articles published in Lancet Neurol Retrieve available abstracts of 146 articles: HTML format

Single Articles

December 2025
1. SCHOLZ SW, Okubadejo NU, Prakash P, Liddelow SA, et al
   Advances in the genetics and pathology of Lewy body dementia.
   Lancet Neurol. 2025;24:1026-1037.
   PubMed     Abstract available
   
   
   
2. 
   Global, regional, and national burden of headache disorders, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
   Lancet Neurol. 2025;24:1005-1015.
   PubMed     Abstract available
   
   
   November 2025
3. FRIEDMAN D
   Advances in understanding sudden unexpected death in people with drug-resistant epilepsy.
   Lancet Neurol. 2025 Nov 21:S1474-4422(25)00423.
   PubMed    
   
   
   
4. NORDESTGAARD AT, Moorthy MV, Cook NR, Rifai N, et al
   High-sensitivity C-reactive protein, LDL cholesterol, lipoprotein(a) and 30-year risk of stroke in healthy women: a prospective, longitudinal cohort study.
   Lancet Neurol. 2025;24:920-930.
   PubMed     Abstract available
   
   
   
5. ETMINAN N, Ruigrok YM, Hackenberg KAM, Vergouwen MDI, et al
   Epidemiology, pathogenesis, and emerging concepts in unruptured intracranial aneurysms.
   Lancet Neurol. 2025;24:945-957.
   PubMed     Abstract available
   
   
   
6. PRETERRE C, Gaultier A, Obadia M, Vignal C, et al
   Intravenous alteplase versus oral aspirin for acute central retinal artery occlusion within 4.5 h of severe vision loss (THEIA): a multicentre, double-dummy, patient-blinded and assessor-blinded, randomised, controlled, phase 3 trial.
   Lancet Neurol. 2025;24:909-919.
   PubMed     Abstract available
   
   
   October 2025
7. SAIDHA S, Green AJ, Leocani L, Vidal-Jordana A, et al
   The use of optical coherence tomography and visual evoked potentials in the 2024 McDonald diagnostic criteria for multiple sclerosis.
   Lancet Neurol. 2025;24:880-892.
   PubMed     Abstract available
   
   
   
8. BARKHOF F, Reich DS, Oh J, Rocca MA, et al
   2024 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI for the diagnosis of multiple sclerosis.
   Lancet Neurol. 2025;24:866-879.
   PubMed     Abstract available
   
   
   
9. MONTALBAN X, Lebrun-Frenay C, Oh J, Arrambide G, et al
   Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria.
   Lancet Neurol. 2025;24:850-865.
   PubMed     Abstract available
   
   
   
10. MAGANA-TELLEZ O, Maganti R, Hupp NJ, Luo X, et al
    Sleep EEG and respiratory biomarkers of sudden unexpected death in epilepsy (SUDEP): a case-control study.
    Lancet Neurol. 2025;24:840-849.
    PubMed     Abstract available
    
    
    
11. RODRIGUES MA, Seiffge D, Samarasekera N, Moullaali TJ, et al
    Association between the Edinburgh CT and genetic diagnostic criteria for cerebral amyloid angiopathy-associated lobar intracerebral haemorrhage and recurrent intracerebral haemorrhage: an individual patient data meta-analysis.
    Lancet Neurol. 2025;24:828-839.
    PubMed     Abstract available
    
    
    September 2025
12. CRAWFORD TO, Servais L, Mercuri E, Kolbel H, et al
    Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial.
    Lancet Neurol. 2025;24:727-739.
    PubMed     Abstract available
    
    
    August 2025
13. PETERS S, Hung SH, Bayley MT, Best KL, et al
    Safety and effectiveness of the Walk 'n Watch structured, progressive exercise protocol delivered by physical therapists for inpatient stroke rehabilitation in Canada: a phase 3, multisite, pragmatic, stepped-wedge, cluster-randomised controlled trial
    Lancet Neurol. 2025;24:643-655.
    PubMed     Abstract available
    
    
    
14. FENG W, Cassarly C, Wittenberg GF, Schlaug G, et al
    Rethinking neuromodulation in stroke: lessons from TRANSPORT2 - Authors' reply.
    Lancet Neurol. 2025;24:637-638.
    PubMed    
    
    
    
15. KWAKKEL G
    Gait training after stroke: are physiotherapists overcautious?
    Lancet Neurol. 2025;24:626-627.
    PubMed    
    
    
    July 2025
16. WANG X, Ren X, Li Q, Ouyang M, et al
    Effects of blood pressure lowering in relation to time in acute intracerebral haemorrhage: a pooled analysis of the four INTERACT trials.
    Lancet Neurol. 2025;24:571-579.
    PubMed     Abstract available
    
    
    
17. WERRING DJ
    Rapid blood pressure lowering after acute intracerebral haemorrhage: time is brain, again.
    Lancet Neurol. 2025;24:558-559.
    PubMed    
    
    
    June 2025
18. SPOSATO LA, Ayan D, Ahmed M, Fridman S, et al
    Extended CT angiography versus standard CT angiography for the detection of cardioaortic thrombus in patients with ischaemic stroke and transient ischaemic attack (DAYLIGHT): a prospective, randomised, open-label, blinded end-point trial.
    Lancet Neurol. 2025;24:489-499.
    PubMed     Abstract available
    
    
    
19. MANLEY GT, Dams-O'Connor K, Alosco ML, Awwad HO, et al
    A new characterisation of acute traumatic brain injury: the NIH-NINDS TBI Classification and Nomenclature Initiative.
    Lancet Neurol. 2025;24:512-523.
    PubMed     Abstract available
    
    
    
20. 
    Safety and efficacy of trehalose in amyotrophic lateral sclerosis (HEALEY ALS Platform Trial): an adaptive, phase 2/3, double-blind, randomised, placebo-controlled trial.
    Lancet Neurol. 2025;24:500-511.
    PubMed     Abstract available
    
    
    
21. MARSAN E, Gutman D, Hohman TJ, Phatak M, et al
    The Path-NeuroDegeneration consortium.
    Lancet Neurol. 2025;24:482.
    PubMed    
    
    
    
22. NOGUEIRA RG, Bhatt N, Haussen DC, Moehlenbruch MA, et al
    Endovascular treatment of distal arterial occlusions: a more distant reality than ever?
    Lancet Neurol. 2025;24:478-480.
    PubMed    
    
    
    
23. GARCIA-ESPERON C, Parsons MW
    Shedding DAYLIGHT on atrial thrombus in hyperacute stroke.
    Lancet Neurol. 2025;24:472-473.
    PubMed    
    
    
    May 2025
24. DONNERS SJA, van Velzen TJ, Cheng SF, Gregson J, et al
    Optimised medical therapy alone versus optimised medical therapy plus revascularisation for asymptomatic or low-to-intermediate risk symptomatic carotid stenosis (ECST-2): 2-year interim results of a multicentre randomised trial.
    Lancet Neurol. 2025;24:389-399.
    PubMed     Abstract available
    
    
    
25. HO JK, Hankey GJ
    Carotid revascularisation for carotid stenosis.
    Lancet Neurol. 2025;24:372-373.
    PubMed    
    
    
    April 2025
26. CAVALCANTE F, Treurniet K, Kaesmacher J, Kappelhof M, et al
    Intravenous thrombolysis before endovascular treatment versus endovascular treatment alone for patients with large vessel occlusion and carotid tandem lesions: individual participant data meta-analysis of six randomised trials.
    Lancet Neurol. 2025;24:305-315.
    PubMed     Abstract available
    
    
    
27. SALMAN RA, Thrippleton MJ
    Pharmacological therapy for cerebral cavernous malformations.
    Lancet Neurol. 2025;24:276-277.
    PubMed    
    
    
    March 2025
28. SCHLAUG G, Cassarly C, Feld JA, Wolf SL, et al
    Safety and efficacy of transcranial direct current stimulation in addition to constraint-induced movement therapy for post-stroke motor recovery (TRANSPORT2): a phase 2, multicentre, randomised, sham-controlled triple-blind trial.
    Lancet Neurol. 2025 Mar 26:S1474-4422(25)00044.
    PubMed     Abstract available
    
    
    
29. MIZIELINSKA S, Hautbergue GM, Gendron TF, van Blitterswijk M, et al
    Amyotrophic lateral sclerosis caused by hexanucleotide repeat expansions in C9orf72: from genetics to therapeutics.
    Lancet Neurol. 2025;24:261-274.
    PubMed     Abstract available
    
    
    
30. VAN DE MUNCKHOF A, van Kammen MS, Tatlisumak T, Krzywicka K, et al
    Direct oral anticoagulants versus vitamin K antagonists for cerebral venous thrombosis (DOAC-CVT): an international, prospective, observational cohort study.
    Lancet Neurol. 2025;24:199-207.
    PubMed     Abstract available
    
    
    February 2025
31. PRICE C
    Neuroprotection in acute ischaemic stroke: reasons for optimism?
    Lancet Neurol. 2025 Feb 4:S1474-4422(25)00007.
    PubMed    
    
    
    
32. TYMIANSKI M, Hill MD, Goyal M, Christenson J, et al
    Safety and efficacy of nerinetide in patients with acute ischaemic stroke enrolled in the early window: a post-hoc meta-analysis of individual patient data from three randomised trials.
    Lancet Neurol. 2025 Feb 4:S1474-4422(24)00515.
    PubMed     Abstract available
    
    
    
33. SHOAMANESH A, Field TS, Coutts SB, Sharma M, et al
    Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controlled trial.
    Lancet Neurol. 2025;24:140-151.
    PubMed     Abstract available
    
    
    
34. LIU R, Zhao J, Rudd AG
    From stroke awareness to stroke action awareness.
    Lancet Neurol. 2025;24:96.
    PubMed    
    
    
    
35. SPOSATO LA, Wachter R
    Anticoagulation for patients with device-detected atrial fibrillation and a history of stroke.
    Lancet Neurol. 2025;24:92-94.
    PubMed    
    
    
    
36. MOENS TG, Da Cruz S, Neumann M, Shelkovnikova TA, et al
    Amyotrophic lateral sclerosis caused by FUS mutations: advances with broad implications.
    Lancet Neurol. 2025;24:166-178.
    PubMed     Abstract available
    
    
    
37. COLEMAN KKL, Berry S, Cummings J, Hsiung GR, et al
    Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trial.
    Lancet Neurol. 2025;24:128-139.
    PubMed     Abstract available
    
    
    
38. HABIB AA, Zhao C, Aban I, Franca MC Jr, et al
    Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.
    Lancet Neurol. 2025;24:117-127.
    PubMed     Abstract available
    
    
    
39. ANTOZZI C, Vu T, Ramchandren S, Nowak RJ, et al
    Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study.
    Lancet Neurol. 2025;24:105-116.
    PubMed     Abstract available
    
    
    January 2025
40. YANG P, Zhang Y, Liu J
    Ischaemic stroke in 2024: progress on multiple fronts.
    Lancet Neurol. 2025;24:7-8.
    PubMed    
    
    
    December 2024
41. GETTINGS JV, Mohammad Alizadeh Chafjiri F, Patel AA, Shorvon S, et al
    Diagnosis and management of status epilepticus: improving the status quo.
    Lancet Neurol. 2024 Dec 2:S1474-4422(24)00430.
    PubMed     Abstract available
    
    
    
42. SHETH KN, Albers GW, Saver JL, Campbell BCV, et al
    Intravenous glibenclamide for cerebral oedema after large hemispheric stroke (CHARM): a phase 3, double-blind, placebo-controlled, randomised trial.
    Lancet Neurol. 2024;23:1205-1213.
    PubMed     Abstract available
    
    
    
43. LIU Q, Mo S, Wu J, Tong X, et al
    Safety and efficacy of early versus delayed acetylsalicylic acid after surgery for spontaneous intracerebral haemorrhage in China (E-start): a prospective, multicentre, open-label, blinded-endpoint, randomised trial.
    Lancet Neurol. 2024;23:1195-1204.
    PubMed     Abstract available
    
    
    November 2024
44. TURC G, Nguyen TN
    Reconsidering prourokinase for acute ischaemic stroke.
    Lancet Neurol. 2024 Nov 28:S1474-4422(24)00474.
    PubMed    
    
    
    
45. LI S, Gu HQ, Feng B, Li H, et al
    Safety and efficacy of intravenous recombinant human prourokinase for acute ischaemic stroke within 4.5 h after stroke onset (PROST-2): a phase 3, open-label, non-inferiority, randomised controlled trial.
    Lancet Neurol. 2024 Nov 28:S1474-4422(24)00436.
    PubMed     Abstract available
    
    
    
46. KRUYT ND, Nederkoorn PJ, Sandset EC, Lyden P, et al
    A cautionary view on blood pressure lowering in patients with acute ischaemic stroke receiving reperfusion therapy.
    Lancet Neurol. 2024 Nov 25:S1474-4422(24)00438.
    PubMed    
    
    
    
47. MUIR KW, Ford GA, Ford I, Wardlaw JM, et al
    Tenecteplase versus alteplase for acute stroke within 4.5 h of onset (ATTEST-2): a randomised, parallel group, open-label trial.
    Lancet Neurol. 2024;23:1087-1096.
    PubMed     Abstract available
    
    
    
48. BRALEY TJ, Ehde DM, Alschuler KN, Little R, et al
    Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm trial.
    Lancet Neurol. 2024;23:1108-1118.
    PubMed     Abstract available
    
    
    
49. PALAIODIMOU L, Tsivgoulis G
    A new standard for thrombolysis in acute ischaemic stroke.
    Lancet Neurol. 2024;23:1064-1065.
    PubMed    
    
    
    October 2024
50. LIM SY, Tan AH, Ahmad-Annuar A, Okubadejo NU, et al
    Uncovering the genetic basis of Parkinson's disease globally: from discoveries to the clinic.
    Lancet Neurol. 2024 Oct 21:S1474-4422(24)00378.
    PubMed     Abstract available
    
    
    
51. VOLOVICI V, Cenzato M, Meling TR
    The European expertise network for open microvascular surgery.
    Lancet Neurol. 2024 Oct 11:S1474-4422(24)00409.
    PubMed    
    
    
    
52. 
    Global, regional, and national burden of stroke and its risk factors, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
    Lancet Neurol. 2024;23:973-1003.
    PubMed     Abstract available
    
    
    
53. WU S, Liu M
    Global burden of stroke: dynamic estimates to inform action.
    Lancet Neurol. 2024;23:952-953.
    PubMed    
    
    
    
54. AMEZCUA L, Rotstein D, Shirani A, Ciccarelli O, et al
    Differential diagnosis of suspected multiple sclerosis: considerations in people from minority ethnic and racial backgrounds in North America, northern Europe, and Australasia.
    Lancet Neurol. 2024;23:1050-1062.
    PubMed     Abstract available
    
    
    
55. CORREALE J, Solomon AJ, Cohen JA, Banwell BL, et al
    Differential diagnosis of suspected multiple sclerosis: global health considerations.
    Lancet Neurol. 2024;23:1035-1049.
    PubMed     Abstract available
    
    
    September 2024
56. CANEVELLI M, Jackson-Tarlton C, Rockwood K
    Frailty for neurologists: perspectives on how frailty influences care planning.
    Lancet Neurol. 2024 Sep 11:S1474-4422(24)00291.
    PubMed     Abstract available
    
    
    
57. OSPEL JM, Ganesh A, Goyal M
    Pragmatic outcomes for stroke research.
    Lancet Neurol. 2024;23:860-862.
    PubMed    
    
    
    
58. YOGENDRAKUMAR V, Lin L, Medcalf RL, Parsons MW, et al
    Improving thrombolysis efficiency for acute ischaemic stroke.
    Lancet Neurol. 2024;23:853-855.
    PubMed    
    
    
    August 2024
59. LABEIT B, Michou E, Trapl-Grundschober M, Suntrup-Krueger S, et al
    Dietary intervention for post-stroke dysphagia - Authors' reply.
    Lancet Neurol. 2024;23:764-765.
    PubMed    
    
    
    
60. SHIMIZU A, Yamaguchi K, Kunieda K, Ohno T, et al
    Dietary intervention for post-stroke dysphagia.
    Lancet Neurol. 2024;23:763-764.
    PubMed    
    
    
    
61. THE LANCET NEUROLOGY
    A real chance to reduce death and disability from stroke.
    Lancet Neurol. 2024;23:749.
    PubMed    
    
    
    July 2024
62. MORIMOTO T, Sakakibara F
    Endovascular thrombectomy for large ischaemic stroke: outcomes beyond 90 days.
    Lancet Neurol. 2024 Jul 26:S1474-4422(24)00290.
    PubMed    
    
    
    
63. THOMALLA G, Fiehler J, Subtil F, Bonekamp S, et al
    Endovascular thrombectomy for acute ischaemic stroke with established large infarct (TENSION): 12-month outcomes of a multicentre, open-label, randomised trial.
    Lancet Neurol. 2024 Jul 26:S1474-4422(24)00278.
    PubMed     Abstract available
    
    
    
64. SCHULTZ SA, Liu L, Schultz AP, Fitzpatrick CD, et al
    gamma-Secretase activity, clinical features, and biomarkers of autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analysis of the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS).
    Lancet Neurol. 2024 Jul 26:S1474-4422(24)00236.
    PubMed     Abstract available
    
    
    
65. BOURCIER R, Marnat G, Dargazanli C, Zhu F, et al
    Safety and efficacy of stent retrievers plus contact aspiration in patients with acute ischaemic anterior circulation stroke and positive susceptibility vessel sign in France (VECTOR): a randomised, single-blind trial.
    Lancet Neurol. 2024;23:700-711.
    PubMed     Abstract available
    
    
    
66. ABDALKADER M, Nguyen TN
    Susceptibility vessel sign and endovascular stroke therapy.
    Lancet Neurol. 2024;23:653-654.
    PubMed    
    
    
    June 2024
67. GAO F, Tong X, Jia B, Wei M, et al
    Bailout intracranial angioplasty or stenting following thrombectomy for acute large vessel occlusion in China (ANGEL-REBOOT): a multicentre, open-label, blinded-endpoint, randomised controlled trial.
    Lancet Neurol. 2024 Jun 21:S1474-4422(24)00186.
    PubMed     Abstract available
    
    
    
68. CAMPBELL BCV
    Durable benefit of thrombectomy 6-24 h after stroke onset.
    Lancet Neurol. 2024 Jun 20:S1474-4422(24)00261.
    PubMed    
    
    
    
69. HUIJBERTS I, Pinckaers FME, Olthuis SGH, van Kuijk SMJ, et al
    Collateral-based selection for endovascular treatment of acute ischaemic stroke in the late window (MR CLEAN-LATE): 2-year follow-up of a phase 3, multicentre, open-label, randomised controlled trial in the Netherlands.
    Lancet Neurol. 2024 Jun 20:S1474-4422(24)00228.
    PubMed     Abstract available
    
    
    
70. PARSONS MW, Yogendrakumar V, Churilov L, Garcia-Esperon C, et al
    Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4.5 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-inferiority trial.
    Lancet Neurol. 2024 Jun 13:S1474-4422(24)00206.
    PubMed     Abstract available
    
    
    
71. TOYODA K
    Tenecteplase versus alteplase in stroke thrombolysis: the last piece of the puzzle?
    Lancet Neurol. 2024 Jun 13:S1474-4422(24)00258.
    PubMed    
    
    
    
72. ALI M, van Etten ES, Akoudad S, Schaafsma JD, et al
    Haemorrhagic stroke and brain vascular malformations in women: risk factors and clinical features.
    Lancet Neurol. 2024;23:625-635.
    PubMed     Abstract available
    
    
    
73. THE LANCET NEUROLOGY
    Forging ahead in haemorrhagic stroke research.
    Lancet Neurol. 2024;23:545.
    PubMed    
    
    
    
74. SISODIYA SM, Gulcebi MI, Fortunato F, Mills JD, et al
    Climate change and disorders of the nervous system.
    Lancet Neurol. 2024;23:636-648.
    PubMed     Abstract available
    
    
    May 2024
75. OLAVARRIA VV
    Challenging the management of blood pressure before intravenous thrombolysis in acute ischaemic stroke.
    Lancet Neurol. 2024 May 15:S1474-4422(24)00208.
    PubMed    
    
    
    
76. ZONNEVELD TP, Vermeer SE, van Zwet EW, Groot AED, et al
    Safety and efficacy of active blood-pressure reduction to the recommended thresholds for intravenous thrombolysis in patients with acute ischaemic stroke in the Netherlands (TRUTH): a prospective, observational, cluster-based, parallel-group study.
    Lancet Neurol. 2024 May 15:S1474-4422(24)00177.
    PubMed     Abstract available
    
    
    
77. SARFO FS, Gebreyohanns M, Akinyemi R, Ebenezer AA, et al
    The African Stroke Organization Conference 2023.
    Lancet Neurol. 2024;23:459-460.
    PubMed    
    
    
    
78. CORTESE I, Norato G, Harrington PR, Usher T, et al
    Biomarkers for progressive multifocal leukoencephalopathy: emerging data for use of JC virus DNA copy number in clinical trials.
    Lancet Neurol. 2024;23:534-544.
    PubMed     Abstract available
    
    
    
79. PELLINEN J, Foster EC, Wilmshurst JM, Zuberi SM, et al
    Improving epilepsy diagnosis across the lifespan: approaches and innovations.
    Lancet Neurol. 2024;23:511-521.
    PubMed     Abstract available
    
    
    April 2024
80. YASSI N, Zhao H, Churilov L, Wu TY, et al
    Tranexamic acid versus placebo in individuals with intracerebral haemorrhage treated within 2 h of symptom onset (STOP-MSU): an international, double-blind, randomised, phase 2 trial.
    Lancet Neurol. 2024 Apr 19:S1474-4422(24)00128.
    PubMed     Abstract available
    
    
    
81. 
    Medical management and surgery versus medical management alone for symptomatic cerebral cavernous malformation (CARE): a feasibility study and randomised, open, pragmatic, pilot phase trial.
    Lancet Neurol. 2024 Apr 17:S1474-4422(24)00096.
    PubMed     Abstract available
    
    
    
82. GUSTAVSSON EK, Follett J, Trinh J, Barodia SK, et al
    RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses.
    Lancet Neurol. 2024 Apr 10:S1474-4422(24)00121.
    PubMed     Abstract available
    
    
    
83. LABEIT B, Michou E, Trapl-Grundschober M, Suntrup-Krueger S, et al
    Dysphagia after stroke: research advances in treatment interventions.
    Lancet Neurol. 2024;23:418-428.
    PubMed     Abstract available
    
    
    
84. SEIFFGE DJ, Cancelloni V, Raber L, Paciaroni M, et al
    Secondary stroke prevention in people with atrial fibrillation: treatments and trials.
    Lancet Neurol. 2024;23:404-417.
    PubMed     Abstract available
    
    
    
85. SPOSATO LA, Andrade JG, Field TS
    Detection of atrial fibrillation in patients after stroke - Authors' reply.
    Lancet Neurol. 2024;23:336-337.
    PubMed    
    
    
    
86. SIONTIS KC, Noseworthy PA, Friedman PA
    Detection of atrial fibrillation in patients after stroke.
    Lancet Neurol. 2024;23:335-336.
    PubMed    
    
    
    
87. KANDEL A, Arjyal A, Karmacharya B, Gajurel B, et al
    Pragmatic solutions for the global burden of stroke.
    Lancet Neurol. 2024;23:334.
    PubMed    
    
    
    
88. FEIGIN VL, Yaria J, Owolabi M
    Pragmatic solutions for the global burden of stroke - Authors' reply.
    Lancet Neurol. 2024;23:334-335.
    PubMed    
    
    
    
89. SCHLOGL M, Quinn TJ
    Pragmatic solutions for the global burden of stroke.
    Lancet Neurol. 2024;23:333-334.
    PubMed    
    
    
    
90. 
    Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
    Lancet Neurol. 2024;23:344-381.
    PubMed     Abstract available
    
    
    February 2024
91. MAZIGHI M, Kohrmann M, Lemmens R, Lyrer PA, et al
    Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a randomised, double-blind, placebo-controlled, phase 1b/2a trial.
    Lancet Neurol. 2024;23:157-167.
    PubMed     Abstract available
    
    
    
92. GANESH A
    Platelet glycoprotein VI inhibition: a promising therapeutic avenue in acute ischaemic stroke.
    Lancet Neurol. 2024;23:125-127.
    PubMed    
    
    
    
93. SIMUNI T, Chahine LM, Poston K, Brumm M, et al
    A biological definition of neuronal alpha-synuclein disease: towards an integrated staging system for research.
    Lancet Neurol. 2024;23:178-190.
    PubMed     Abstract available
    
    
    
94. CHAPLEAU M, La Joie R, Yong K, Agosta F, et al
    Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis.
    Lancet Neurol. 2024;23:168-177.
    PubMed     Abstract available
    
    
    January 2024
95. SHARMA M, Molina CA, Toyoda K, Bereczki D, et al
    Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial.
    Lancet Neurol. 2024;23:46-59.
    PubMed     Abstract available
    
    
    
96. KHATRI P
    Anticoagulants to prevent recurrent non-cardioembolic stroke.
    Lancet Neurol. 2024;23:3-5.
    PubMed    
    
    
    
97. ANDERSON CS
    Stroke advances in 2023: a new horizon for the management of intracerebral haemorrhage.
    Lancet Neurol. 2024;23:12-13.
    PubMed    
    
    
    December 2023
98. BRIGO F
    The (hi)story of stroke.
    Lancet Neurol. 2023;22:1110.
    PubMed    
    
    
    
99. UCHIYAMA S
    Anticoagulation in people with atrial fibrillation after intracranial haemorrhage.
    Lancet Neurol. 2023;22:1091-1092.
    PubMed    
    
    
    
100. ABBOTT A, Schott L, Gao L, Budincevic H, et al
     Carotid artery overtreatment in the USA.
     Lancet Neurol. 2023;22:1102-1103.
     PubMed    
     
     
     November 2023
101. KOPCZAK A, Stringer MS, van den Brink H, Kerkhofs D, et al
     Effect of blood pressure-lowering agents on microvascular function in people with small vessel diseases (TREAT-SVDs): a multicentre, open-label, randomised, crossover trial.
     Lancet Neurol. 2023;22:991-1004.
     PubMed     Abstract available
     
     
     
102. RUBIANO AM, Lee K
     Traumatic brain injury research: homogenising heterogeneity.
     Lancet Neurol. 2023;22:973-975.
     PubMed    
     
     
     
103. ADAMS D, Sekijima Y, Conceicao I, Waddington-Cruz M, et al
     Hereditary transthyretin amyloid neuropathies: advances in pathophysiology, biomarkers, and treatment.
     Lancet Neurol. 2023;22:1061-1074.
     PubMed     Abstract available
     
     
     October 2023
104. MIRELMAN A, Rochester L, Simuni T, Hausdoff JM, et al
     Digital mobility measures to predict Parkinson's disease.
     Lancet Neurol. 2023 Oct 18:S1474-4422(23)00376.
     PubMed    
     
     
     
105. SPOSATO LA, Field TS, Schnabel RB, Wachter R, et al
     Towards a new classification of atrial fibrillation detected after a stroke or a transient ischaemic attack.
     Lancet Neurol. 2023 Oct 11:S1474-4422(23)00326.
     PubMed     Abstract available
     
     
     
106. AL-SHAHI SALMAN R, Stephen J, Tierney JF, Lewis SC, et al
     Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials.
     Lancet Neurol. 2023 Oct 11:S1474-4422(23)00315.
     PubMed     Abstract available
     
     
     
107. KAMEL H
     Reassessing the implications of atrial fibrillation detected after stroke.
     Lancet Neurol. 2023 Oct 11:S1474-4422(23)00406.
     PubMed    
     
     
     
108. BRUSCA SB, Albert MA
     Balancing the scales of adversity: a socioecological approach to reducing the global burden of stroke and cardiovascular disease.
     Lancet Neurol. 2023 Oct 9:S1474-4422(23)00386.
     PubMed    
     
     
     
109. WATKINS DA
     Policy priorities for preventing stroke-related mortality and disability worldwide.
     Lancet Neurol. 2023 Oct 9:S1474-4422(23)00387.
     PubMed    
     
     
     
110. FEIGIN VL, Owolabi MO
     Pragmatic solutions to reduce the global burden of stroke: a World Stroke Organization-Lancet Neurology Commission.
     Lancet Neurol. 2023 Oct 6:S1474-4422(23)00277.
     PubMed    
     
     
     
111. MARCUCCI M, Chan MTV, Smith EE, Absalom AR, et al
     Prevention of perioperative stroke in patients undergoing non-cardiac surgery.
     Lancet Neurol. 2023;22:946-958.
     PubMed     Abstract available
     
     
     
112. IZZY S, Grashow R, Radmanesh F, Chen P, et al
     Long-term risk of cardiovascular disease after traumatic brain injury: screening and prevention.
     Lancet Neurol. 2023;22:959-970.
     PubMed     Abstract available
     
     
     September 2023
113. HUGGER SS, Do TP, Ashina H, Goicochea MT, et al
     Migraine in older adults.
     Lancet Neurol. 2023 Sep 13:S1474-4422(23)00206.
     PubMed     Abstract available
     
     
     
114. LABEIT B, Michou E, Hamdy S, Trapl-Grundschober M, et al
     The assessment of dysphagia after stroke: state of the art and future directions.
     Lancet Neurol. 2023;22:858-870.
     PubMed     Abstract available
     
     
     
115. FENG W
     Diagnosis of post-stroke dysphagia: towards better treatment.
     Lancet Neurol. 2023;22:778-779.
     PubMed    
     
     
     
116. OSPEL JM, Goyal M
     Prehospital triage in acute stroke: which questions to ask?
     Lancet Neurol. 2023;22:771-772.
     PubMed    
     
     
     
117. D'GAMA AM, Mulhern S, Sheidley BR, Boodhoo F, et al
     Evaluation of the feasibility, diagnostic yield, and clinical utility of rapid genome sequencing in infantile epilepsy (Gene-STEPS): an international, multicentre, pilot cohort study.
     Lancet Neurol. 2023;22:812-825.
     PubMed     Abstract available
     
     
     
118. GUTERUD M, Fagerheim Bugge H, Roislien J, Kramer-Johansen J, et al
     Prehospital screening of acute stroke with the National Institutes of Health Stroke Scale (ParaNASPP): a stepped-wedge, cluster-randomised controlled trial.
     Lancet Neurol. 2023;22:800-811.
     PubMed     Abstract available
     
     
     August 2023
119. ODDO M, Taccone FS, Petrosino M, Badenes R, et al
     The Neurological Pupil index for outcome prognostication in people with acute brain injury (ORANGE): a prospective, observational, multicentre cohort study.
     Lancet Neurol. 2023 Aug 28:S1474-4422(23)00271.
     PubMed     Abstract available
     
     
     
120. RIZIG M, Bandres-Ciga S, Makarious MB, Ojo OO, et al
     Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study.
     Lancet Neurol. 2023 Aug 23:S1474-4422(23)00283.
     PubMed     Abstract available
     
     
     
121. SOLOMON AJ, Arrambide G, Brownlee WJ, Flanagan EP, et al
     Differential diagnosis of suspected multiple sclerosis: an updated consensus approach.
     Lancet Neurol. 2023;22:750-768.
     PubMed     Abstract available
     
     
     
122. MEADOR KJ, Cohen MJ, Loring DW, Matthews AG, et al
     Cognitive outcomes at age 3 years in children with fetal exposure to antiseizure medications (MONEAD study) in the USA: a prospective, observational cohort study.
     Lancet Neurol. 2023;22:712-722.
     PubMed     Abstract available
     
     
     
123. MAYNARD G, Kannan R, Liu J, Wang W, et al
     Soluble Nogo-Receptor-Fc decoy (AXER-204) in patients with chronic cervical spinal cord injury in the USA: a first-in-human and randomised clinical trial.
     Lancet Neurol. 2023;22:672-684.
     PubMed     Abstract available
     
     
     
124. GILADI N, Alcalay RN, Cutter G, Gasser T, et al
     Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
     Lancet Neurol. 2023;22:661-671.
     PubMed     Abstract available
     
     
     July 2023
125. ENGLISH C, Ramage E
     Secondary stroke prevention: more questions than answers.
     Lancet Neurol. 2023 Jul 25:S1474-4422(23)00278.
     PubMed    
     
     
     
126. SCHWARZBACH CJ, Eichner FA, Rucker V, Hofmann AL, et al
     The structured ambulatory post-stroke care program for outpatient aftercare in patients with ischaemic stroke in Germany (SANO): an open-label, cluster-randomised controlled trial.
     Lancet Neurol. 2023 Jul 14:S1474-4422(23)00216.
     PubMed     Abstract available
     
     
     
127. DESBOROUGH MJR, Al-Shahi Salman R, Stanworth SJ, Havard D, et al
     Desmopressin for patients with spontaneous intracerebral haemorrhage taking antiplatelet drugs (DASH): a UK-based, phase 2, randomised, placebo-controlled, multicentre feasibility trial.
     Lancet Neurol. 2023;22:557-567.
     PubMed     Abstract available
     
     
     
128. FRISONI GB, van der Flier W
     STRIVEing to describe small vessel disease.
     Lancet Neurol. 2023;22:548-549.
     PubMed    
     
     
     
129. GRANIT V, Benatar M, Kurtoglu M, Miljkovic MD, et al
     Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study.
     Lancet Neurol. 2023;22:578-590.
     PubMed     Abstract available
     
     
     
130. CORBOY JR, Fox RJ, Kister I, Cutter GR, et al
     Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial.
     Lancet Neurol. 2023;22:568-577.
     PubMed     Abstract available
     
     
     
131. MEISEL A
     Are CAR T cells the answer to myasthenia gravis therapy?
     Lancet Neurol. 2023;22:545-546.
     PubMed    
     
     
     June 2023
132. VAN DER MERWE J
     Stroke care quality-why recognition matters.
     Lancet Neurol. 2023;22:471.
     PubMed    
     
     
     
133. HAYWARD KS, Bernhardt J
     Aspiring to restore arm and hand function after stroke.
     Lancet Neurol. 2023;22:464-465.
     PubMed    
     
     
     May 2023
134. DUERING M, Biessels GJ, Brodtmann A, Chen C, et al
     Neuroimaging standards for research into small vessel disease-advances since 2013.
     Lancet Neurol. 2023 May 23:S1474-4422(23)00131.
     PubMed     Abstract available
     
     
     
135. KOEMANS EA, Chhatwal JP, van Veluw SJ, van Etten ES, et al
     Progression of cerebral amyloid angiopathy: a pathophysiological framework.
     Lancet Neurol. 2023 May 23:S1474-4422(23)00114.
     PubMed     Abstract available
     
     
     
136. HOWARD JF JR, Bresch S, Genge A, Hewamadduma C, et al
     Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.
     Lancet Neurol. 2023;22:395-406.
     PubMed     Abstract available
     
     
     
137. BRIL V, Druzdz A, Grosskreutz J, Habib AA, et al
     Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
     Lancet Neurol. 2023;22:383-394.
     PubMed     Abstract available
     
     
     
138. KASKI D, Koohi N, Haider S, Chandratheva A, et al
     The hyperacute vestibular syndrome: ear or brain?
     Lancet Neurol. 2023;22:377-378.
     PubMed    
     
     
     April 2023
139. WU S, Anderson CS
     Antiplatelets for secondary stroke prevention in China.
     Lancet Neurol. 2023 Apr 27:S1474-4422(23)00130.
     PubMed    
     
     
     
140. PAN Y, Meng X, Yuan B, Johnston SC, et al
     Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial.
     Lancet Neurol. 2023 Apr 27:S1474-4422(23)00113.
     PubMed     Abstract available
     
     
     
141. LAVALLEE PC, Charles H, Albers GW, Caplan LR, et al
     Effect of atherosclerosis on 5-year risk of major vascular events in patients with transient ischaemic attack or minor ischaemic stroke: an international prospective cohort study.
     Lancet Neurol. 2023;22:320-329.
     PubMed     Abstract available
     
     
     
142. SAMUELS N, van de Graaf RA, Mulder MJHL, Brown S, et al
     Admission systolic blood pressure and effect of endovascular treatment in patients with ischaemic stroke: an individual patient data meta-analysis.
     Lancet Neurol. 2023;22:312-319.
     PubMed     Abstract available
     
     
     
143. BERNHARDT J, Corbett D, Dukelow S, Savitz S, et al
     The International Stroke Recovery and Rehabilitation Alliance.
     Lancet Neurol. 2023;22:295-296.
     PubMed    
     
     
     
144. MAZIGHI M
     The quest for optimal blood pressure management after stroke.
     Lancet Neurol. 2023;22:285-286.
     PubMed    
     
     
     
145. FEIGIN VL, Brainin M, Martins SCO
     The polypill from a public-health perspective.
     Lancet Neurol. 2023;22:294-295.
     PubMed    
     
     
     March 2023
146. TSIVGOULIS G, Katsanos AH, Sandset EC, Turc G, et al
     Thrombolysis for acute ischaemic stroke: current status and future perspectives.
     Lancet Neurol. 2023 Mar 9:S1474-4422(22)00519.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Stroke is free of charge.